Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular Pathways

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

Yun Dai and Steven Grant
Yun Dai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Grant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-09-1029 Published January 2010
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Chk1 in the DDR signaling network. DNA damage (e.g., DSBs, SSBs, and stalled replication forks) generates ssDNA that initiates ATR-mediated Chk1 activation. In this context, the ATR/ATPIP complex is recruited to ssDNA lesions via binding of ATRIP with RPA that recognizes and coats ssDNA. In conjunction with recruited/activated sensors and mediators, ATR phosphorylates Chk1 at two canonical sites (Ser345 and S317), directly leading to its activation without the homodimerization and intramolecular trans-autophosphorylation that is required for Chk2 activation. Activated Chk1 then phosphorylates diverse downstream effectors, which in turn are involved in cell cycle checkpoints (i.e., intra-S-phase, G2/M-phase, and G1/S-phase checkpoints), the DNA replication checkpoint, and the mitotic spindle checkpoint, as well as DNA repair, apoptosis, and transcription. Consequently, Chk1 is a kinase central for the DDR signaling network, thereby representing a particularly attractive target in anticancer therapeutics.

Tables

  • Figures
  • Table 1.

    Checkpoint abrogators in clinical trials

    CompoundTargetAgents in combinationCancer typesStatus (number of trials)
    UCN-01Chk1, other kinasesMonotherapyRefractory systemic anaplastic large cell and mature T-cell lymphomaPhase II, active
    IrinotecanResistant solid tumors or locally recurrent or metastatic triple-negative breast cancerPhase I, active
    PerifosineRelapsed or refractory acute leukemia, chronic myelogenous leukemia, high-risk myelodysplastic syndromePhase I, active
    MonotherapyAdvanced or metastatic renal cell carcinomaPhase II, closed
    MonotherapyMetastatic melanoma phase II, closed
    MonotherapyRefractory solid tumors or lymphomaPhase I, closed
    MonotherapyAdvanced solid tumors and chronic lymphoproliferative disordersPhase I, completed
    FludarabineRelapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphomaPhase I and II, closed
    FludarabineRecurrent or refractory low-grade or indolent lymphoid malignanciesPhase I, completed
    FluorouracilGemcitabine-refractory metastatic pancreatic cancerPhase II, completed
    FluorouracilAdvanced or refractory solid tumorsPhase I, completed
    FluorouracilMetastatic or unresectable solid tumorsPhase I, completed
    + Leucovorin (triple)
    TopotecanRecurrent, persistent, or progressive advanced ovarian cancersPhase I and II, completed
    TopotecanRelapsed or progressed small cell lung cancer platinum-based chemotherapyPhase II, closed
    CytarabineRefractory or relapsed acute myelogenous leukemia or myelodysplastic syndromePhase I, closed
    CisplatinAdvanced solid tumorsPhase I (2), completed
    CarboplatinAdvanced solid tumorsPhase I, completed
    GemcitabineUnresectable or metastatic adenocarcinoma of the pancreasPhase I, completed
    PrednisoneRefractory solid tumors or lymphomasPhase I, closed
    AZD7762Chk1, Chk2GemcitabineAdvanced solid malignanciesPhase I (2), active
    IrinotecanAdvanced solid malignanciesPhase I, active
    LY2603618Chk2GemcitabinePancreatic cancerPhase I, active
    PemetrexedMetastatic non-small cell lung cancerPhase I, active
    CBT501Chk1, Chk2CisplatinSolid tumorsPhase I, active (1)/closed (1)
    CisplatinMalignant pleural mesotheliomaPhase II, active
    PemetrexedNon-small cell lung cancerPhase II, active
    + Cisplatin (triple)
    PF-00477736Chk1, Chk2GemcitabineAdvanced solid tumorsPhase I, active
    SCH 900776Chk1GemcitabineSolid tumors or lymphomaPhase I, active
    CytarabineAcute leukemiaPhase I, active
    XL844Chk1, Chk2GemcitabineAdvanced malignancies (solid tumor and lymphoma)Phase I, closed
    MK-1775Wee1MonotherapyAdvanced solid tumorsPhase I, active
    Gemcitabine
    Cisplatin
    Carboplatin
    7-AADHsp90, Chk1IrinotecanSolid tumorsPhase I, active

    NOTE: Data from http://www.cancer.gov; http://www.clinicaltrial.gov.

PreviousNext
Back to top
Clinical Cancer Research: 16 (2)
January 2010
Volume 16, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Yun Dai and Steven Grant
Clin Cancer Res January 15 2010 (16) (2) 376-383; DOI: 10.1158/1078-0432.CCR-09-1029

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Yun Dai and Steven Grant
Clin Cancer Res January 15 2010 (16) (2) 376-383; DOI: 10.1158/1078-0432.CCR-09-1029
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Checkpoint Signaling Cascades
    • Chk1 Activation Upstream Signals
    • Current Models for Chk1 Activation Mechanisms
    • Chk1 in DNA Damage Checkpoints
    • Other Chk1 Functions
    • Clinical-Translational Advances
    • Alternative Strategies: An Example Emphasizing the Link between Chk1 Inhibitors and the Ras/MEK/ERK Survival Pathway
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Targeting of the Liver Microenvironment
  • Targeting the Protein Kinase Wee1 in Cancer
  • Metabolic Control of Histone Methylation and Gene Expression
Show more Molecular Pathways
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement